BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33004416)

  • 1. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
    Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
    Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
    [No Abstract]   [Full Text] [Related]  

  • 2. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
    Somasundaram R; Jensen CT; Tingvall-Gustafsson J; Åhsberg J; Okuyama K; Prasad M; Hagman JR; Wang X; Soneji S; Strid T; Ungerbäck J; Sigvardsson M
    Blood; 2021 Jun; 137(22):3037-3049. PubMed ID: 33619557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
    Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
    J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency.
    Prasad MA; Ungerbäck J; Åhsberg J; Somasundaram R; Strid T; Larsson M; Månsson R; De Paepe A; Lilljebjörn H; Fioretos T; Hagman J; Sigvardsson M
    Blood; 2015 Jun; 125(26):4052-9. PubMed ID: 25838350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early B-cell factor 1 regulates the expansion of B-cell progenitors in a dose-dependent manner.
    Åhsberg J; Ungerbäck J; Strid T; Welinder E; Stjernberg J; Larsson M; Qian H; Sigvardsson M
    J Biol Chem; 2013 Nov; 288(46):33449-61. PubMed ID: 24078629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
    Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
    [No Abstract]   [Full Text] [Related]  

  • 7. EBF1, PAX5, and MYC: regulation on B cell development and association with hematologic neoplasms.
    Li L; Zhang D; Cao X
    Front Immunol; 2024; 15():1320689. PubMed ID: 38318177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct promoters mediate the regulation of Ebf1 gene expression by interleukin-7 and Pax5.
    Roessler S; Györy I; Imhof S; Spivakov M; Williams RR; Busslinger M; Fisher AG; Grosschedl R
    Mol Cell Biol; 2007 Jan; 27(2):579-94. PubMed ID: 17101802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Pax5 Exploits Sca1-BCR-ABL
    Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
    Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
    Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
    Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
    Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
    Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
    Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
    J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
    Swaminathan S; Huang C; Geng H; Chen Z; Harvey R; Kang H; Ng C; Titz B; Hurtz C; Sadiyah MF; Nowak D; Thoennissen GB; Rand V; Graeber TG; Koeffler HP; Carroll WL; Willman CL; Hall AG; Igarashi K; Melnick A; Müschen M
    Nat Med; 2013 Aug; 19(8):1014-22. PubMed ID: 23852341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebf1 in DNA repair and leukemogenesis.
    Georgopoulos K
    Blood; 2015 Jun; 125(26):3969-71. PubMed ID: 26113531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined heterozygous loss of Ebf1 and Pax5 allows for T-lineage conversion of B cell progenitors.
    Ungerbäck J; Åhsberg J; Strid T; Somasundaram R; Sigvardsson M
    J Exp Med; 2015 Jun; 212(7):1109-23. PubMed ID: 26056231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.
    Bullerwell CE; Robichaud PP; Deprez PML; Joy AP; Wajnberg G; D'Souza D; Chacko S; Fournier S; Crapoulet N; Barnett DA; Lewis SM; Ouellette RJ
    Sci Rep; 2021 Jan; 11(1):1537. PubMed ID: 33452395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
    Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
    PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
    Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
    Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
    Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
    Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-dependent role for EBF1 in repressing non-B-cell-specific genes.
    Lukin K; Fields S; Guerrettaz L; Straign D; Rodriguez V; Zandi S; Månsson R; Cambier JC; Sigvardsson M; Hagman J
    Eur J Immunol; 2011 Jun; 41(6):1787-93. PubMed ID: 21469119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.